🚀Clinical Research

Preventive Steroids Show No Clear Link to Higher Transgene Expression in a Canine Hemophilia A Model

Journal of thrombosis and haemostasis : JTH·August 22, 2026AI Curation
Preventive Steroids Show No Clear Link to Higher Transgene Expression in a Canine Hemophilia A Model
✨AI Summary (Beta)Beta

Background

A study of seven dogs with severe hemophilia A found no clear association between preventive steroid administration and increased transgene expression after gene therapy. Adeno-associated virus (AAV) gene therapy has been approved for adults with severe hemophilia A. The source mentions a subsequent commercial withdrawal but does not explain its cause. The durability of treatment effects, variation between patients, and the mechanisms behind elevated liver enzymes remain insufficiently understood.

The study asked how preventive corticosteroid administration affects transgene expression and safety after gene therapy. The researchers compared steroid-treated and control groups in a canine model of severe hemophilia A.

Key findings

The dogs received an AAV5-based vector encoding canine factor VIII (AAV5-cFVIII) at a dose of 6×10¹³ vector genomes (vg) per kilogram of body weight. Four dogs received oral prednisolone at 1 mg/kg per day, starting three hours before vector administration, with the dose tapered over six weeks. The three control dogs received the vector without steroids.

For two years after vector administration, all dogs showed therapeutic factor VIII coagulant activity (FVIII:C, 8.7–56.1%). Whole-blood clotting time also improved, and the annual bleeding frequency fell from 6.11 episodes before treatment to 1.42 afterward (P=0.016). These results reflect outcomes before and after gene therapy across all dogs and should be distinguished from a between-group comparison of any added steroid effect.

At two years, mean FVIII:C measured by chromogenic substrate assay (CSA) was 39.1% in the steroid group and 29.5% in controls. This difference was strongly influenced by one female in the steroid group, whose activity was high after day 54. The abstract does not report statistical significance for the between-group difference, so the mean values alone do not establish a benefit from preventive steroid administration.

Regardless of steroid use, mean FVIII:C at two years was 49.3% in females and 9.1% in males. However, the abstract does not provide the number of animals by sex or an analysis separating sex effects from other variables. These observations alone cannot establish a role for hormonal or genetic factors or explain how the vector becomes established in the liver.

Preventive steroids were reported to have no effect on transient post-treatment increases in inflammatory cytokines, anti-AAV antibody formation, or alanine aminotransferase (ALT) levels. The researchers performed percutaneous liver biopsies when ALT exceeded twice the upper limit of normal. In one dog in the steroid group, ALT exceeded 4.3 times the upper limit of normal at week 18, but long-term FVIII:C expression was unaffected. The biopsy showed widespread but minimal periportal lymphocyte and neutrophil infiltration, consistent with nonspecific, very mild hepatitis.

Meaning and outlook

In this study, preventive steroid use was not clearly associated with increased transgene expression. This does not demonstrate that steroids have no effect or that the two groups are equivalent. The study included seven dogs, and the available abstract does not establish whether allocation was randomized or whether the study was blinded.

The difference in activity by sex is an observation that requires further validation. Larger studies should examine sex composition alongside individual expression patterns to clarify its interpretation. These findings should not be extrapolated to support sex-specific dosing, hormone therapy, or changes to preventive steroid prescribing in people.

The study design and results are described in the Journal of Thrombosis and Haemostasis article abstract.

INTRODUCTION: Prior to commercial withdrawal, adeno-associated virus (AAV) gene therapy was approved for the treatment of adults with severe hemophilia A. Mechanisms underlying variability, durability, and liver transaminitis are largely uncharacterized. OBJECTIVES: To evaluate the effects of prophylactic corticosteroid administration on AAV gene therapy outcomes in severe hemophilia A dogs. METHODS: Seven hemophilia A dogs received 6e13 vector genomes/kg AAV5-canine factor VIII (AAV5-cFVIII). Four dogs received oral prednisolone (1 mg/kg/day) starting 3 hours pre-infusion with dose-tapering over 6 weeks; three control dogs received no corticosteroids. Percutaneous liver biopsies were performed on detection of alanine transaminase (ALT) >2-fold the upper limit of normal (ULN). RESULTS: All dogs expressed therapeutic FVIII:C (8.7-56.1%), improved whole blood clot time, and decreased bleeding rates (pre=6.11 vs. post=1.42 bleeds/year, p=0.016) over 2 years post-AAV5-cFVIII. Corticosteroid-treated dogs demonstrated a modest increase in mean FVIII:C at two years by chromogenic substrate assay (CSA) (39.1%) compared with controls (29.5%), driven by one female with markedly elevated FVIII:C from day 54 onward. When analyzed by sex, all female dogs exhibited increased mean FVIII:C CSA at 2 years (49.3%) compared with males (9.1%), regardless of prophylactic corticosteroid use. Prophylactic corticosteroids did not impact transient post-treatment elevations of pro-inflammatory cytokines, anti-AAV antibody formation, or ALT levels. One corticosteroid-treated dog experienced ALT >4.3-fold ULN at 18 weeks without impacting long-term FVIII:C expression. A liver biopsy showed diffuse, minimal periportal lymphocyte and neutrophil infiltration, consistent with non-specific minimal hepatitis. CONCLUSIONS: Prophylactic corticosteroids were not clearly associated with increased transgene expression in hemophilia A dogs.

💬Why it matters:

Gene therapy development requires distinguishing overall improvement after treatment from the added benefit of an adjunctive drug. This study observed reduced bleeding and therapeutic FVIII activity, but those outcomes cannot be attributed to preventive steroids. The findings may inform the design of future preclinical studies that assess FVIII activity, bleeding rates, ALT, and immune responses separately while comparing each animal’s course. In particular, the strong influence of one female’s high activity on the difference between group means illustrates why sex composition and variation between individuals should be considered alongside group averages. The study does not support changing doses or steroid prescribing in people, and both the reproducibility and cause of the observed sex difference require further investigation.

💬 Comments

0 comments
Please log in to comment
Loading...

BioPlayground

Reading, linking, and lawful quotation stay open; high-speed bulk collection and unauthorized redistribution do not.

Unless stated otherwise, content rights belong to BioPlayground or the relevant rights holder.